Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05851053
Other study ID # 202100903
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact Daan Brandenbarg, PhD
Phone 0031628475305
Email d.brandenbarg@umcg.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both. However, it is still unclear whether patients with BC are at increased risk of long-term cardiac dysfunction due to the adverse effects of these therapies. In a cross-sectional study in primary care, a comparison on cardiac dysfunction between 350 BC survivors and 350 age- and general practitioner (GP)- matched controls without cancer was made. In that study, BC survivors were at increased risk of mild systolic cardiac dysfunction (left ventricle ejection fraction (LVEF)< 54%). By contrast, there was no significant difference in an LVEF < 50% or in diastolic dysfunction. To date it remains uncertain whether the mild or subclinical dysfunction we observed predicts further cardiac deterioration. Consequently, the translation of these results into guidelines for the daily practice of the GP is unclear. Objective: The aim of the here proposed study is to clarify whether cardiac function in survivors of BC should be monitored by GPs, by assessing whether an unselected population of long-term BC survivors is at increased risk of developing cardiac dysfunction, whether in this group at-risk subgroups exists, and what factors are associated with the highest risk. Study design: A new assessment of cardiac function among women included in the BLOC-I study. This produces a longitudinal matched cohort design consisting of two cohorts in primary care. Study population: Survivors of BC, diagnosed ≥11 years ago who received chemotherapy and/or radiotherapy, and a matched reference population with no history of cancer. All participants participated in the Breast cancer Long-term Outcome of Cardiac function (BLOC-I) study. Main study parameters/endpoints: Left ventricular systolic dysfunction. Systolic cardiac dysfunction is defined as a LVEF <54/50/45%.


Recruitment information / eligibility

Status Recruiting
Enrollment 455
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Patients who previously took part in de BLOC-I study will be included. These criteria were: - females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago - treatment with chemotherapy and/or radiotherapy. Exclusion Criteria: - Patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their GP. Exclusion criteria for the BC survivors in the BLOC-I study were: - metastatic disease at the time of BC diagnosis; - BC treatment after 80 years of age; - history of treatment for other types of cancer.

Study Design


Intervention

Diagnostic Test:
Echocardiography
During echocardiography, the following parameters will be assessed: Dimensions Left ventricle function Right ventricle function Valves: Aorta valve and pulmonic valve Other findings such as: frequency, rhythm, quality

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Boerman LM, Maass SWMC, van der Meer P, Gietema JA, Maduro JH, Hummel YM, Berger MY, de Bock GH, Berendsen AJ. Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study. Eur J Cancer. 2017 Aug;81:56-65. doi: 10.1016/j.ejca.2017.05.013. Epub 2017 Jun 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Patient characteristics age, BMI, menopausal state through study completion (from Ocotober 2022 - December 2024)
Other Physical activity Changes in Physical Acticity measured with Short Questionnaire to Assess Health-enhancing physical activity (SQUASH) through study completion (from Ocotober 2022 - December 2024)
Other Depression Symptoms of depression measured with Hospital Anxiety and Depression Scale - Despression (HADS-D) through study completion (from Ocotober 2022 - December 2024)
Other Anxiety Symptoms of anxiety measured with Hospital Anxiety and Depression Scale - Anxiety (HADS-A) through study completion (from Ocotober 2022 - December 2024)
Other Fatigue Multidimensional assessment of fatigue mesaured with Multidimensional Fatigue Index - 20 (MFI-20). through study completion (from Ocotober 2022 - December 2024)
Other Use of cardiovascular medication Use of cardiovascular medication based on electronic patient records through study completion (from Ocotober 2022 - December 2024)
Other Smoking behavior (self-reported pack years) Smoking behavior through study completion (from Ocotober 2022 - December 2024)
Primary Left ventricular systolic dysfunction Prevalance of systolic cardiac dysfunction defined as a LVEF <54% through study completion (from Ocotober 2022 - December 2024)
Secondary Clinically used LVEF cut-off points <45% and <50% Prevalance of systolic cardiac dysfunction defined as a LVEF <45% and <50% through study completion (from Ocotober 2022 - December 2024)
Secondary Course of cardiac function Rate of change of systolic and diastolic cardiac function by change in LVEF through study completion (from Ocotober 2022 - December 2024)
Secondary Cardiovascular diseases Prevalence of cardiovascular diseases obtained from electronic patient records through study completion (from Ocotober 2022 - December 2024)
Secondary Symptoms of hearth failure Clinical symptoms of heart failure measured using a self-constructed questionnaire through study completion (from Ocotober 2022 - December 2024)
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy